These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 15542428

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [Abstract] [Full Text] [Related]

  • 3. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
    Breast Cancer Res; 2008 Jan; 10(5):R88. PubMed ID: 18928543
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH, Hayes DF.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract] [Full Text] [Related]

  • 6. HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
    Ferretti G, Di Cosimo S, Giannarelli D, Carlini P, Papaldo P, Alimonti A, Fabi A, Mandalà M, Milella M, Ruggeri EM, Cognetti F.
    J Clin Oncol; 2004 Feb 01; 22(3):568-9. PubMed ID: 14752083
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Endocrine therapy for postmenopausal breast cancer (role of cycline D1)].
    Manikhas AG, Skvortsov VA, Manikhas GM, Raskin GA, Oganesian AS, Shemerovskiĭ AK.
    Vopr Onkol; 2011 Feb 01; 57(5):641-4. PubMed ID: 22238936
    [No Abstract] [Full Text] [Related]

  • 9. Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
    Jansen MP, Foekens JA, Klijn JG, Berns EM.
    J Natl Cancer Inst; 2005 Dec 21; 97(24):1851-2; author reply 1852-3. PubMed ID: 16368948
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tamoxifen for early breast cancer.
    Nurs Times; 2005 Dec 21; 97(25):41. PubMed ID: 11957988
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Individualized care for patients with cancer - a work in progress.
    Bast RC, Hortobagyi GN.
    N Engl J Med; 2004 Dec 30; 351(27):2865-7. PubMed ID: 15591336
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
    Rydén L, Stendahl M, Jonsson H, Emdin S, Bengtsson NO, Landberg G.
    Breast Cancer Res Treat; 2005 Jan 30; 89(2):135-43. PubMed ID: 15692755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.